CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: George Simeon (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A-3 Preferred Shares	$		Common Shares (2942560)		Indirect
Series B Preferred Shares	$		Common Shares (211567)		Indirect

Footnotes

F1: The Series A-3 Preferred Shares and the Series B Preferred Shares are convertible at any time on a one-for-one basis into common shares of the Issuer ("Common Shares") at the holder's election and are convertible automatically into Common Shares upon the closing of the Issuer's initial public offering. These securities do not have an expiration date.

F2: The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares reported herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein, if any.